• Je něco špatně v tomto záznamu ?

Positive effects of different drug forms of silybin in the treatment of metabolic syndrome

M. Poruba, Z. Matušková, L. Kazdová, O. Oliyarnyk, H. Malínská, I. Tozzi di Angelo, R. Večeřa

. 2015 ; 64 (Suppl 4) : S507-S512.
. 2015 ; () : S507-S512.

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16031173

Silymarin and silybin are widely used for their hepatoprotective properties. Our previous studies confirm positive effect of silymarin on lipoprotein profile and lipid homeostasis. Advanced drug forms may improve the bioavailability of these compounds. In this study, we investigate the effects of silybin in different drug forms (standardized silybin, micronized silybin, and silybin in form of phytosomes) on dyslipidemia and glucose metabolism in hereditary hypertriglyceridemic (HHTg) rats. Male HHTg rats were divided into four groups of seven animals and were fed by experimental diets. Silybin significantly decreased serum level of triglycerides in groups of rats fed by standardized silybin and silybin in form of phytosomes compared to control group. Results show that silybin did not affect the total cholesterol level, but significantly increased the levels of HDL cholesterol in all groups of animals. Silybin in a standardized form had the highest hypotriglyceridemic effect. On the other hand, the micronized form has caused the highest increase of protective HDL and most significantly decreased glucose and insulin levels. Our results suggest that silybin is probably responsible for some positive properties of silymarin. Subsequent dose-dependent studies of silybin action may reveal the intensity of its positive effects on lipid and glucose parameters.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16031173
003      
CZ-PrNML
005      
20170418102736.0
007      
ta
008      
161101s2015 xr d f 000 0|ENG||
009      
AR
024    7_
$a 10.33549/physiolres.933235 $2 doi
035    __
$a (PubMed)26681080
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a ENG
044    __
$a xr
100    1_
$a Poruba, Martin $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacký University Olomouc, Czech Republic $7 xx0230224
245    10
$a Positive effects of different drug forms of silybin in the treatment of metabolic syndrome / $c M. Poruba, Z. Matušková, L. Kazdová, O. Oliyarnyk, H. Malínská, I. Tozzi di Angelo, R. Večeřa
520    9_
$a Silymarin and silybin are widely used for their hepatoprotective properties. Our previous studies confirm positive effect of silymarin on lipoprotein profile and lipid homeostasis. Advanced drug forms may improve the bioavailability of these compounds. In this study, we investigate the effects of silybin in different drug forms (standardized silybin, micronized silybin, and silybin in form of phytosomes) on dyslipidemia and glucose metabolism in hereditary hypertriglyceridemic (HHTg) rats. Male HHTg rats were divided into four groups of seven animals and were fed by experimental diets. Silybin significantly decreased serum level of triglycerides in groups of rats fed by standardized silybin and silybin in form of phytosomes compared to control group. Results show that silybin did not affect the total cholesterol level, but significantly increased the levels of HDL cholesterol in all groups of animals. Silybin in a standardized form had the highest hypotriglyceridemic effect. On the other hand, the micronized form has caused the highest increase of protective HDL and most significantly decreased glucose and insulin levels. Our results suggest that silybin is probably responsible for some positive properties of silymarin. Subsequent dose-dependent studies of silybin action may reveal the intensity of its positive effects on lipid and glucose parameters.
650    _2
$a zvířata $7 D000818
650    _2
$a farmaceutická chemie $7 D002626
650    _2
$a HDL-cholesterol $x krev $7 D008076
650    _2
$a glukosa $x metabolismus $7 D005947
650    _2
$a hypertriglyceridemie $x krev $x farmakoterapie $x genetika $7 D015228
650    _2
$a inzulin $x krev $7 D007328
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a metabolický syndrom $x krev $x farmakoterapie $x genetika $7 D024821
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani transgenní $7 D055647
650    _2
$a silymarin $x chemie $x terapeutické užití $7 D012838
650    _2
$a výsledek terapie $7 D016896
650    _2
$a triglyceridy $x krev $7 D014280
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Rácová, Zuzana $7 xx0109661 $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacký University Olomouc, Czech Republic
700    1_
$a Kazdová, Ludmila, $d 1938- $7 xx0053119 $u Center of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Oliyarnyk, Olena $7 xx0095365 $u Center of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Malínská, Hana $7 xx0158953 $u Center of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Tozzi di Angelo, Igor, $d 1963- $7 xx0096668 $u Department of Exercise Medicine and Cardiovascular Rehabilitation, University Hospital Olomouc, Czech Republic
700    1_
$a Večeřa, Rostislav, $d 1965- $7 mzk2004236742 $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacký University Olomouc, Czech Republic
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 64, Suppl 4 (2015), s. S507-S512
773    0_
$t Prof. Jaroslav Květina celebrates his 85th birthday $g (2015), s. S507-S512 $w MED00191412
856    41
$u http://www.biomed.cas.cz/physiolres/ $y domovská stránka časopisu
910    __
$a ABA008 $b A 4120 $c 266 $y 4 $z 0
990    __
$a 20161101 $b ABA008
991    __
$a 20170418103044 $b ABA008
999    __
$a ok $b bmc $g 1173613 $s 955831
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 64 $c Suppl 4 $d S507-S512 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
BMC    ##
$a 2015 $d S507-S512 $m Prof. Jaroslav Květina celebrates his 85th birthday $x MED00191412
LZP    __
$b NLK118 $a Pubmed-20161101
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace